Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1065

1.

The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.

Tang D, Xu S, Zhang Q, Zhao W.

Med Oncol. 2012 Jun;29(2):526-33. doi: 10.1007/s12032-011-9948-2. Epub 2011 Apr 26.

PMID:
21519872
2.

Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray.

He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T.

Med Oncol. 2012 Jun;29(2):406-10. doi: 10.1007/s12032-011-9832-0. Epub 2011 Jan 25.

PMID:
21264529
3.

Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.

Choi JE, Kang SH, Lee SJ, Bae YK.

Ann Surg Oncol. 2015 Jan;22(1):82-9. doi: 10.1245/s10434-014-3984-z. Epub 2014 Aug 22.

PMID:
25145503
4.

Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.

Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O.

Hum Pathol. 2012 Jan;43(1):23-30. doi: 10.1016/j.humpath.2011.04.011. Epub 2011 Jul 20.

PMID:
21777944
5.

Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.

Li CY, Zhang S, Zhang XB, Wang P, Hou GF, Zhang J.

Asian Pac J Cancer Prev. 2013;14(6):3779-84.

6.

Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.

Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu N, Lan F, Liu Y, Yan S, Dong X, Cai L.

Cancer Epidemiol. 2013 Dec;37(6):985-92. doi: 10.1016/j.canep.2013.08.005. Epub 2013 Sep 5.

PMID:
24012693
7.

Novel prognostic markers for patients with triple-negative breast cancer.

Zhou L, Li K, Luo Y, Tian L, Wang M, Li C, Huang Q.

Hum Pathol. 2013 Oct;44(10):2180-7. doi: 10.1016/j.humpath.2013.03.021. Epub 2013 Jul 8.

PMID:
23845466
8.

Expression and clinical significance of androgen receptor in triple negative breast cancer.

Luo X, Shi YX, Li ZM, Jiang WQ.

Chin J Cancer. 2010 Jun;29(6):585-90.

9.

Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.

McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, Castle EP, Gray RJ, Wasif N, Goetz MP, Hawse JR, Henry TJ, Barrett MT, Cunliffe HE, Pockaj BA.

Ann Surg Oncol. 2014 Feb;21(2):361-7. doi: 10.1245/s10434-013-3260-7. Epub 2013 Sep 18.

PMID:
24046116
10.

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.

11.

CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis.

Albasri A, Aleskandarany M, Benhasouna A, Powe DG, Ellis IO, Ilyas M, Green AR.

Breast Cancer Res Treat. 2011 Feb;126(1):47-54. doi: 10.1007/s10549-010-0890-3.

PMID:
20390342
12.

Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer.

Kim S, Jung WH, Koo JS.

Tumour Biol. 2012 Oct;33(5):1681-94. doi: 10.1007/s13277-012-0424-1. Epub 2012 May 27.

PMID:
22638807
13.

Immunohistochemically defined subtypes and outcome of apocrine breast cancer.

Dellapasqua S, Maisonneuve P, Viale G, Pruneri G, Mazzarol G, Ghisini R, Mazza M, Iorfida M, Rotmensz N, Veronesi P, Luini A, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2013 Apr;13(2):95-102. doi: 10.1016/j.clbc.2012.11.004. Epub 2012 Dec 14.

PMID:
23245877
14.

Expression of androgen receptors in primary breast cancer.

Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, Lee KS.

Ann Oncol. 2010 Mar;21(3):488-92. doi: 10.1093/annonc/mdp510. Epub 2009 Nov 3.

15.

Prognostic value of bcl-2 expression among women with breast cancer in Libya.

Ermiah E, Buhmeida A, Khaled BR, Abdalla F, Salem N, Pyrhönen S, Collan Y.

Tumour Biol. 2013 Jun;34(3):1569-78. doi: 10.1007/s13277-013-0687-1. Epub 2013 Feb 16.

PMID:
23417836
16.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

17.

Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.

Xiao M, Jia S, Wang H, Wang J, Huang Y, Li Z.

J Cancer Res Clin Oncol. 2013 Apr;139(4):661-7. doi: 10.1007/s00432-012-1368-y. Epub 2013 Jan 6.

PMID:
23292099
18.

Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.

Arapantoni-Dadioti P, Valavanis C, Gavressea T, Tzaida O, Trihia H, Lekka I.

J BUON. 2012 Apr-Jun;17(2):277-83.

PMID:
22740206
19.

Primary breast cancer phenotypes associated with propensity for central nervous system metastases.

Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R.

Cancer. 2006 Aug 15;107(4):696-704.

20.

Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.

Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L, Amadori D.

Oncology. 2013;84(3):150-7. doi: 10.1159/000345795. Epub 2012 Dec 19.

PMID:
23257904
Items per page

Supplemental Content

Write to the Help Desk